Pay in 4 interest-free payments of $7.35 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Three further Phase 3 trial results in the TRIUMPH programme are due before the end of 2026: TRIUMPH-2 in obesity with type 2 diabetes, TRIUMPH-3 in obesity with established cardiovascular disease (with further safety information relevant to higher-risk populations), and obstructive sleep apnoea
Clinical Trial Evidence and Findings in Female Participants Phase 2 trial data (Jastreboff et al., NEJM, 2023) showed dose-dependent weight reduction and metabolic improvements, but sex-disaggregated results were not published, so female-specific efficacy cannot yet be confirmed
By incorporating GLP-1 medications after VSG, patients can potentially avoid the need for additional surgeries and still achieve significant weight loss
PMID: 40278267 Int J Mol Sci MTX-211 Inhibits GSH Synthesis through Keap1/NRF2/GCLM Axis and Exerts Antitumor Effects in Bladder Cancer
For research purposes where compound integrity matters, verifiable Janoshik testing is the more important factor than the lowest price
The medication is administered as a weekly subcutaneous injection
US$ 24.98
US$ 22.91
US$ 27.30
US$ 20.75
US$ 20.22
